Ameriprise Financial Inc Amylyx Pharmaceuticals, Inc. Transaction History

Ameriprise Financial Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$18.08 - $23.45 $4,592 - $5,956	-254 Reduced 0.2%	129,918 $2.38 Million
Q2 2023 Aug 14, 2023	SELL	$20.98 - $31.42 $1.73 Million - $2.59 Million	-82,281 Reduced 38.73%	130,172 $2.81 Million
Q1 2023 May 15, 2023	BUY	$27.71 - $40.93 $232,126 - $342,870	8,377 Added 4.1%	212,453 $6.23 Million
Q4 2022 Feb 14, 2023	BUY	$29.75 - $39.26 $4.05 Million - $5.35 Million	136,201 Added 200.66%	204,076 $7.54 Million
Q3 2022 Nov 14, 2022	SELL	$17.15 - $30.92 $533,022 - $960,993	-31,080 Reduced 31.41%	67,875 $1.91 Million
Q2 2022 Aug 15, 2022	BUY	$6.85 - $19.93 $114,018 - $331,734	16,645 Added 20.22%	98,955 $1.91 Million
Q1 2022 May 16, 2022	BUY	$12.85 - $32.9 $1.06 Million - $2.71 Million	82,310 New	82,310 $1.06 Million

127

44.4M

235K

530K

Ticker AMLX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,533,200
Market Cap $227M
Description
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...

Get notified when there are updates to the investment portfolio of Ameriprise Financial Inc, based on Form 13F filings with the SEC.

Stay updated on Ameriprise Financial Inc with notifications on news.